HIGHLIGHTS
- who: Yanan Zhu from the (UNIVERSITY) have published the article: Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center, in the Journal: (JOURNAL)
- what: The authors aimed to evaluate the efficacy, safety of SMART (rituximab + lenalidomide + BTKi) regimen and SMART-START regimen as a first-line treatment in elderly or unfit DLBCL patients. The study shows that SMART regimen is an effective and safe therapy for elderly DLBCL patients, and SMART-START regimen can be used in unfit . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.